Cangrelor is a P2Y12 inhibitor used as an antiplatelet drug for intravenous application.
ChEBI: A nucleoside triphosphate analogue that is 5'-O-[({[dichloro(phosphono)methyl](hydroxy)phosphoryl}oxy)(hydroxy)phosphoryl]adenosine carrying additional 2-(methylsulfanyl)ethyl and (3,3,3-trifluoropropyl)sulfanyl substituents at positions
N6 and C2 respectively. Used (in the form of its tetrasodium salt) as an intravenous antiplatelet drug that prevents formation of harmful blood clots in the coronary arteries.
Direct P2Y12 platelet receptor antagonist:
Antiplatelet for patients undergoing a PCI
Cangrelor tetrasodium (10 mg/kg) not only significantly decreases BLM-induced release of inflammatory cytokines (PF4, CD40 L and MPO), but also decreases the increment of platelets, neutrophils and platelet-neutrophil aggregates in the fibrotic lung and in the peripheral blood of BLM-treated mice[2].
Cangrelor is deactivated rapidly in the plasma by
dephosphorylation to form its main metabolite, a
nucleoside. Following a 2 micrograms/kg/min infusion of
[3
H] cangrelor, 58% was found in urine and the remaining
35% was found in faeces, presumably following biliary
excretion.
